|
Dosage/Direction for Use
Oral Postmenopausal osteoporosis Adult: 2 g daily. Elderly: No dosage adjustment needed. Renal impairment: No dosage adjustment needed.
|
||||
|
Administration
Should be taken on an empty stomach. Take on an empty stomach between meals, preferably at bedtime at least 2 hr after food, milk, milk products or Ca supplements. Mix only w/ plain water & drink immediately.
|
||||
|
Contraindications
Patients w/ current or previous venous thromboembolic events including deep vein thrombosis and pulmonary embolism; temporary or permanent immobilisation due to post-surgical recovery or prolonged bed rest; current or history of ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease; uncontrolled HTN. Lactation.
|
||||
|
Special Precautions
Renal impairment. Pregnancy.
|
||||
|
Adverse Reactions
Headache, GI disturbances, eczema, dermatitis; memory loss, consciousness disturbances, seizures, pyrexia, peripheral oedema, confusion, bronchial hyperreactivity. Angioedema, rash, urticaria, pruritus. Transient increases in creatine kinase activity (reversible).
Potentially Fatal: Toxic epidermal necrolysis, Stevens-Johnson syndrome, and drug rash w/ eosinophilia and systemic symptoms. |
||||
|
Drug Interactions
May reduce the absorption of oral tetracycline and quinolone antibiotics. Medicinal products containing Ca may reduce strontium ranelate bioavailability.
|
||||
|
Food Interaction
Food, milk and derivative products containing Ca may reduce strontium ranelate bioavailability.
|
||||
|
Lab Interference
May interfere w/ determination of serum and urinary Ca.
|
||||
|
Action
Strontium ranelate stimulates bone formation, osteoblast precursor replication and collagen synthesis. Decreasing osteoclast differentiation and resorbing activity, it reduces bone resorption resulting in a rebalance of bone turnover in favour of bone formation.
Absorption: Food, milk and derivative products containing Ca may reduce bioavailability by approx 60-70%. Absolute bioavailability: Approx 25%. Time to peak plasma concentration: 3-5 hr. Distribution: Volume of distribution: 1 L/kg. Plasma protein binding: Low (25%). Metabolism: Not metabolised. Excretion: Via kidneys and GI tract. Half-life: Approx 60 hr. |
||||
|
CIMS Class
|
||||
|
ATC Classification
M05BX03 - strontium ranelate ; Belongs to the class of other drugs affecting bone structure and mineralization. Used in the treatment of bone diseases.
|
Sign Out
